7DC Stock Overview
A diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 7DC from our risk checks.
Diaceutics PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.34 |
| 52 Week High | UK£1.56 |
| 52 Week Low | UK£0.96 |
| Beta | 0.60 |
| 11 Month Change | -6.29% |
| 3 Month Change | -11.26% |
| 1 Year Change | 28.85% |
| 33 Year Change | 6.35% |
| 5 Year Change | 22.37% |
| Change since IPO | 16.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7DC | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.2% | 3.5% | 0.8% |
| 1Y | 28.8% | 6.5% | 8.6% |
Return vs Industry: 7DC exceeded the German Life Sciences industry which returned 5.4% over the past year.
Return vs Market: 7DC exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 7DC volatility | |
|---|---|
| 7DC Average Weekly Movement | 3.0% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7DC has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 7DC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 184 | Ryan Keeling | www.diaceutics.com |
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. The company offers DXRX, a diagnostic commercialisation platform for precision medicine that integrates multiple pipelines of diagnostic testing data from network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and the physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports.
Diaceutics PLC Fundamentals Summary
| 7DC fundamental statistics | |
|---|---|
| Market cap | €117.46m |
| Earnings (TTM) | -€3.41m |
| Revenue (TTM) | €31.28m |
3.8x
P/S Ratio-34.4x
P/E RatioIs 7DC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7DC income statement (TTM) | |
|---|---|
| Revenue | UK£26.10m |
| Cost of Revenue | UK£4.36m |
| Gross Profit | UK£21.74m |
| Other Expenses | UK£24.58m |
| Earnings | -UK£2.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 83.30% |
| Net Profit Margin | -10.90% |
| Debt/Equity Ratio | 0% |
How did 7DC perform over the long term?
See historical performance and comparison